Your Article Summary
See Latest ArticlesManufacturing a rapid biologic response
Drug Development Research, 06/19/09
Latham PW - Unfortunately, this kind of stockpiling is very expensive, and does not provide protection against novel threats. Fortunately, there currently exist many new technologies that, when combined strategically, have the potential to significantly reduce the time and cost associated with the PD and manufacturing of biologic countermeasures.
Today in Major Studies...keeping you current
Receive free subspecialty "5-minute updates" via email
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
Investigational New Drugs, 12/18/09
Evaluation of Treatment Satisfaction in Children with Allergic Disease Treated with an Antihistamine: An International, Non-Interventional, Retrospective Study
Clinical Drug Investigation, 12/11/09
Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America
Sanofi-aventis, 12/10/09